SUMMARY Serum or IgM fraction from two patients with a demyelinating neuropathy and IgM monoclonal antibodies to myelin-associated glycoprotein were injected in three different animal species. There were no clinical, electrophysiological or morphological signs of demyelination in either chronic or acute passive transfer experiments. These results suggest that the pathogenesis of this human demyelinating neuropathy may be more complex than has been assumed. Several recent reports have described a demyelinating neuropathy in the setting of an IgM gammopathy with antibody activity to a myelin antigen referred to as myelin-associated glycoprotein. ' -3 This well established clinical association, together with the presence of wide separation of the myelin lamellae that has been shown systematically in these cases,24 suggests that the demyelination may Chronic experiments: (1) Two adult guinea pigs received an initial dose of human IgM (40 mg/kg), the test animal received IgM from patient PB while the other animal served as control. One day later the animals received an immunosuppressive dose of cyclophosphamide (300 mg/ kg). Thereafter the animals received intraperitoneal injections of human IgM (40 mg/kg) every third day during 20 weeks. Blood samples were obtained by cardiac puncture after 6 and 20 weeks of treatment to determine the levels of circulating human IgM by rate immunonephelometry (Beckman) and to test for anti-myelin-associated glycoprotein activity.2 Motor nerve conduction velocity was measured at both sciatic nerves with the anaesthetised animals.' Measurements were made every 2 weeks.
(2) One adult marmoset (Callithrixjacchus) received doses of human IgM (patient PB), ranging from 300-800 mg/kg, every other day during 13 weeks. The injections were given into the dorsal musculature and in part subcutaneously. At the end of the experiment blood was taken to determine the level of circulating human IgM. Motor nerve conduction velocity was measured as described7 every week. (3) In an effort to improve the accessibility of the target antigen to the injected IgM, newborn rabbits were used. Four, 2-day-old rabbits housed with the mother received intraperitoneal injections of human IgM (50 mg/kg) every other day for 4 weeks. The two test animals received IgM from patient AK while the other two served as controls. At the end of the experiment blood was taken from the animals to determine the levels of circulating human IgM and to test for anti-myelin-associated glycoprotein activity.
At the end of all of the above experiments animals were killed and the sciatic nerves were rapidly dissected and Steck, Murray, Justafre, Meier, Toyka, Heininger, Stoll prepared for immunocytochemistry using the PAP method' and for light and electron microscopy.7 Acute experiment: Six adult rabbits were anaesthetised and, after lumbar laminectomy, they received a single intrathecal injection of human serum (0-3 to 0 5 ml). Two test animals were injected with serum from patient PB, two with serum from patient AK and two with control serum. Animals were killed after 3 or 10 days. The lumbo-sacral spinal roots and the cauda equina were removed and prepared for immunocytochemistry using the PAP method and for light and electron microscopy.
Results
All of the animals injected with human IgM on a chronic basis were found to have detectable quantities of human IgM in the circulation, levels ranged from 1 g/l in the experiment with guinea pigs to it 24 '-A*:L it -.
15 gIl, or more, in the experiments with rabbits and monkey. Immunoblotting studies confirmed that the sera of the test animals contained human antibody to myelin-associated glycoprotein while the sera of the control animals did not.
None of the animals involved in acute or chronic passive transfer experiments showed neurological deficit during the observation period. Electrophysiological measurements made during the experiments (with guinea pigs and monkey) failed to show any slowing of motor nerve conduction velocity. Light and electron microscopy revealed no evidence of nerve damage suggestive of a polyneuropathy. Teased fibre preparations displayed no evidence of paranodal or segmental demyelination. Direct immunocytochemical studies performed on paraffin sections of sciatic nerve (chronic experiments) or lumbo-sacral roots (acute experiment) failed to reveal deposits of human IgM in nerve myelin. In the monkey but not the other species, these studies showed the IgM to be located at the perineurium (fig a) . In contrast, indirect immunocytochemical studies confirmed that the human anti-myelin-associated glycoprotein IgM bound specifically to nerve myelin in the species used for these experiments (fig b) . Discussion   Fig (a Passive transfer of serum from patients with autoimmune diseases such as myasthenia gravis" or Lambert-Eaton syndrome,'" has been used to demonstrate the pathogenic role of circulating immunoglobulins. Although a pathogenic role of monoclonal anti-myelin-associated glycoprotein IgM antibodies found in patients with a demyelinating neuropathy has been postulated, this has not yet been positively demonstrated, except for a preliminary report" where intraneural injections were used, which is technically questionable. We chose therefore the passive transfer of intraperitoneally or intramuscularly applied immunoglobulins, an approach which has been shown to be effective in producing morphological and electrophysiological changes in peripheral nerves of animals receiving monoclonal IgM from patients with myelomatous polyneuropathy. 12 For these transfer experiments we have used convenient laboratory species in which myelin-associated glycoprotein has been shown to crossreact with the human monoclonal IgM. 
